Balyasny Asset Management’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $7.2M | Sell |
118,697
-1,222,647
| -91% | -$71.3M | 0.01% | 1187 |
|
|
2025
Q4 | $72.4M | Sell |
1,341,344
-450,167
| -25% | -$21.7M | 0.09% | 242 |
|
|
2025
Q3 | $80.8M | Buy |
1,791,511
+1,746,372
| +3,869% | +$81.6M | 0.1% | 222 |
|
|
2025
Q2 | $2.09M | Buy |
+45,139
| New | +$2.22M | ﹤0.01% | 1708 |
|
|
2025
Q1 | – | Sell |
-347,220
| Closed | -$20.2M | – | 2813 |
|
|
2024
Q4 | $19.6M | Sell |
347,220
-515,384
| -60% | -$28.8M | 0.03% | 677 |
|
|
2024
Q3 | $44.6M | Buy |
862,604
+854,600
| +10,677% | +$40.1M | 0.07% | 348 |
|
|
2024
Q2 | $332K | Sell |
8,004
-46,320
| -85% | -$2.07M | ﹤0.01% | 2200 |
|
|
2024
Q1 | $2.95M | Sell |
54,324
-22,594
| -29% | -$1.15M | 0.01% | 1417 |
|
|
2023
Q4 | $3.95M | Sell |
76,918
-960,724
| -93% | -$50.4M | 0.01% | 1206 |
|
|
2023
Q3 | $60.2M | Buy |
1,037,642
+147,039
| +17% | +$9.01M | 0.12% | 219 |
|
|
2023
Q2 | $57M | Buy |
890,603
+288,296
| +48% | +$19.3M | 0.13% | 224 |
|
|
2023
Q1 | $41.7M | Buy |
+602,307
| New | +$42.5M | 0.1% | 270 |
|
|
2022
Q4 | – | Sell |
-718,488
| Closed | -$54.2M | – | 2796 |
|
|
2022
Q3 | $51.1M | Buy |
718,488
+239,352
| +50% | +$17.4M | 0.16% | 147 |
|
|
2022
Q2 | $36.9M | Buy |
479,136
+29,171
| +6% | +$2.22M | 0.12% | 226 |
|
|
2022
Q1 | $32.9M | Buy |
+449,965
| New | +$30.2M | 0.1% | 256 |
|
|
2021
Q4 | – | Sell |
-530,438
| Closed | -$31.1M | – | 2250 |
|
|
2021
Q3 | $31.4M | Buy |
530,438
+415,856
| +363% | +$27.4M | 0.13% | 220 |
|
|
2021
Q2 | $7.66M | Sell |
114,582
-532,898
| -82% | -$34.7M | 0.04% | 585 |
|
|
2021
Q1 | $40.9M | Buy |
647,480
+238,438
| +58% | +$14.8M | 0.2% | 117 |
|
|
2020
Q4 | $25.4M | Buy |
+409,042
| New | +$25.2M | 0.14% | 200 |
|
|
2020
Q3 | – | Sell |
-12,094
| Closed | -$728K | – | 1303 |
|
|
2020
Q2 | $711K | Sell |
12,094
-315,551
| -96% | -$18.9M | 0.01% | 879 |
|
|
2020
Q1 | $18.3M | Buy |
327,645
+232,090
| +243% | +$14.2M | 0.22% | 135 |
|
|
2019
Q4 | $6.13M | Buy |
+95,555
| New | +$5.47M | 0.04% | 545 |
|
|
2019
Q3 | – | Sell |
-66,761
| Closed | -$3.14M | – | 1186 |
|
|
2019
Q2 | $3.03M | Sell |
66,761
-269,704
| -80% | -$12.6M | 0.02% | 761 |
|
|
2019
Q1 | $16.1M | Buy |
336,465
+65,168
| +24% | +$3.25M | 0.11% | 275 |
|
|
2018
Q4 | $14.1M | Sell |
271,297
-804,944
| -75% | -$43.2M | 0.1% | 279 |
|
|
2018
Q3 | $66.8M | Buy |
1,076,241
+521,635
| +94% | +$31M | 0.3% | 72 |
|
|
2018
Q2 | $30.7M | Buy |
554,606
+122,271
| +28% | +$6.6M | 0.14% | 198 |
|
|
2018
Q1 | $27.3M | Sell |
432,335
-679,353
| -61% | -$43.7M | 0.11% | 247 |
|
|
2017
Q4 | $68.1M | Sell |
1,111,688
-441,171
| -28% | -$27.6M | 0.21% | 112 |
|
|
2017
Q3 | $99M | Buy |
1,552,859
+763,719
| +97% | +$44.6M | 0.39% | 51 |
|
|
2017
Q2 | $44M | Buy |
789,140
+103,618
| +15% | +$5.64M | 0.18% | 147 |
|
|
2017
Q1 | $37.3M | Sell |
685,522
-1,033,840
| -60% | -$56.7M | 0.17% | 143 |
|
|
2016
Q4 | $100M | Buy |
1,719,362
+320,373
| +23% | +$17.5M | 0.54% | 19 |
|
|
2016
Q3 | $75.4M | Buy |
1,398,989
+1,301,480
| +1,335% | +$83.6M | 0.44% | 55 |
|
|
2016
Q2 | $7.17M | Sell |
97,509
-14,151
| -13% | -$1,000K | 0.05% | 434 |
|
|
2016
Q1 | $7.13M | Sell |
111,660
-240,340
| -68% | -$15.2M | 0.04% | 474 |
|
|
2015
Q4 | $24.2M | Sell |
352,000
-865,180
| -71% | -$57.2M | 0.17% | 176 |
|
|
2015
Q3 | $72.1M | Buy |
+1,217,180
| New | +$77.2M | 0.53% | 34 |
|
|
2015
Q2 | – | Sell |
-267,300
| Closed | -$17.2M | – | 1148 |
|
|
2015
Q1 | $17.2M | Buy |
+267,300
| New | +$16.7M | 0.14% | 225 |
|
Other funds holding BMY
VCM
VPM
Balyasny Asset Management's BMY Position: Q1 2026 in Review
Balyasny Asset Management reduced its Bristol-Myers Squibb (BMY) stake by 91% in Q1 2026, selling an estimated $71.3M and leaving 118,697 shares worth $7.2M. The position accounts for 0.01% of the portfolio, ranked #1187.
Balyasny Asset Management first reported a position in BMY in Q1 2015 and has held it in 39 quarters since. The position peaked at $100M in Q4 2016. 2,519 funds tracked by Wall St. Rank hold BMY as of Q1 2026.
- Balyasny Asset Management held 118,697 shares of Bristol-Myers Squibb worth $7.2M as of Q1 2026.
- Balyasny Asset Management sold 1,222,647 Bristol-Myers Squibb shares in Q1 2026, an estimated $71.3M.
- Bristol-Myers Squibb made up 0.01% of Balyasny Asset Management's portfolio in Q1 2026, its #1187 holding.
- Balyasny Asset Management first reported a position in Bristol-Myers Squibb in Q1 2015 and has held it in 39 quarters since.
- Balyasny Asset Management's Bristol-Myers Squibb position peaked at $100M in Q4 2016.
- 2,519 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.
Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.